pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·2h ago·1 min read
save

WuXi Bio sells majority stake in chromatography resin maker Bestchrom; Cabaletta adds new CDMO partner

Aug 20, 2026·read at Endpoints ↗DealNeutral

WuXi Bio announced it will divest its 51.1% equity interest in Bestchrom, a Shanghai-based supplier of chromatography resins.

The sale will transfer control to an unnamed third party, marking WuXi Bio's move to streamline its manufacturing portfolio.

In a separate development, contract development and manufacturing organization Cabaletta has named another CDMO partner to expand its service network.

The announcement also noted that SK pharmteco is pursuing expansion projects in Ireland, though details were not provided.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “WuXi Bio to offload chromatography unit; Cabaletta names another CDMO partner”

read at Endpoints ↗
77 words · retrieved 1h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
CRO/CDMO2

related stories

  • 1d agoKolon TissueGene cuts 37 US staffers after Phase 3 failBioSpace
  • Jul 28The FDA was all in on AI. Will that change?BioPharma Dive
  • Jul 28Acrosian debuts as AI-focused biometrics CROFierce Biotech
  • Jul 28As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskBioSpace
  • Jul 27From confidence to capital: Positioning biotech for the next growth cycleBioPharma Dive